These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 36633811)

  • 21. Givosiran for the treatment of acute hepatic porphyria.
    Ricci A; Ventura P
    Expert Rev Clin Pharmacol; 2022 Apr; 15(4):383-393. PubMed ID: 35531651
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Elevated homocysteine is negatively correlated with plasma cystathionine β-synthase activity in givosiran-treated patients.
    Keibler MA; Sridharan GV; Sweetser MT; Ticau S
    JIMD Rep; 2024 Jul; 65(4):262-271. PubMed ID: 38974609
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Model-based analysis for the population pharmacokinetics of iberdomide and its major active metabolite in healthy subjects and patients with relapsed and refractory multiple myeloma.
    Cheng Y; Xue Y; Chen L; Masin M; Maciag P; Peluso T; Zhou S; Li Y
    Br J Clin Pharmacol; 2023 Jan; 89(1):316-329. PubMed ID: 35981078
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A randomized, placebo-controlled study of givosiran in patients with acute hepatic porphyrias (ENVISION): Final (36-month) analysis of the Taiwan Cohort.
    Lee MJ; Kuo HC; Chou LN; Sweetser MT; Wang JD
    J Formos Med Assoc; 2024 Jun; 123(6):679-686. PubMed ID: 38044204
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Case Report: Lack of Response to Givosiran in a Case of ALAD Porphyria.
    Graff E; Anderson KE; Levy C
    Front Genet; 2022; 13():867856. PubMed ID: 35991568
    [No Abstract]   [Full Text] [Related]  

  • 26. Leading RNA Interference Therapeutics Part 2: Silencing Delta-Aminolevulinic Acid Synthase 1, with a Focus on Givosiran.
    de Paula Brandão PR; Titze-de-Almeida SS; Titze-de-Almeida R
    Mol Diagn Ther; 2020 Feb; 24(1):61-68. PubMed ID: 31792921
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Population Pharmacokinetic Modeling of Benralizumab in Adult and Adolescent Patients with Asthma.
    Yan L; Wang B; Chia YL; Roskos LK
    Clin Pharmacokinet; 2019 Jul; 58(7):943-958. PubMed ID: 30854591
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost savings with hemin versus givosiran for the treatment of patients with acute intermittent porphyria (AIP).
    Massachi S; Epstein J; Hurd J; Bonkovsky HL
    J Med Econ; 2020 Dec; 23(12):1441-1449. PubMed ID: 33043761
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Population Pharmacokinetic Modeling of Fluticasone Furoate, Umeclidinium Bromide, and Vilanterol in Patients with Asthma, Using Data from a Phase IIIA Study (CAPTAIN).
    Yang S; Lee LA; Sule N; Fowler A; Peachey G
    Clin Pharmacokinet; 2021 Jul; 60(7):887-896. PubMed ID: 33598874
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hereditary Coproporphyria in Which the Patient's Course Improved after the Discontinuation of Givosiran.
    Ozaki N; Hayashi Y; Kiyota A
    Intern Med; 2024 Nov; 63(21):2961-2964. PubMed ID: 38462517
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacokinetics and concentration-effect analysis of intravenous RGD891, a platelet GPIIb/IIIa antagonist, using mixed-effects modeling (NONMEM).
    Zannikos PN; Rohatagi S; Jensen BK; DePhillips SL; Rhodes GR
    J Clin Pharmacol; 2000 Oct; 40(10):1129-40. PubMed ID: 11028252
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Population Pharmacokinetics Study of Nemonoxacin Among Chinese Patients With Moderate Hepatic Impairment.
    Kang Y; Li Y; Xu F; Zhang J; Wang K; Chen Y; Wu J; Guo B; Yu J; Zhang Y
    Clin Ther; 2019 Mar; 41(3):505-517.e0. PubMed ID: 30819510
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Population pharmacokinetics of ibandronate in Caucasian and Japanese healthy males and postmenopausal females.
    Pillai G; Gieschke R; Goggin T; Barrett J; Worth E; Steimer JL
    Int J Clin Pharmacol Ther; 2006 Dec; 44(12):655-67. PubMed ID: 17190376
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Population pharmacokinetic analysis of tepotinib, an oral MET kinase inhibitor, including data from the VISION study.
    Xiong W; Papasouliotis O; Jonsson EN; Strotmann R; Girard P
    Cancer Chemother Pharmacol; 2022 May; 89(5):655-669. PubMed ID: 35385993
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Challenges in diagnosis and management of acute hepatic porphyrias: from an uncommon pediatric onset to innovative treatments and perspectives.
    Marcacci M; Ricci A; Cuoghi C; Marchini S; Pietrangelo A; Ventura P
    Orphanet J Rare Dis; 2022 Apr; 17(1):160. PubMed ID: 35392955
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Population pharmacokinetics of doxorubicin: establishment of a NONMEM model for adults and children older than 3 years.
    Kontny NE; Würthwein G; Joachim B; Boddy AV; Krischke M; Fuhr U; Thompson PA; Jörger M; Schellens JH; Hempel G
    Cancer Chemother Pharmacol; 2013 Mar; 71(3):749-63. PubMed ID: 23314734
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Population Pharmacokinetics of Galcanezumab, an Anti-CGRP Antibody, Following Subcutaneous Dosing to Healthy Individuals and Patients With Migraine.
    Kielbasa W; Quinlan T
    J Clin Pharmacol; 2020 Feb; 60(2):229-239. PubMed ID: 31482569
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Population Pharmacokinetics (PK) and Pharmacodynamics (PD) Analysis of LY3015014, a Monoclonal Antibody to Protein Convertase Subtilisin/Kexin Type 9 (PCSK9) in Healthy Subjects and Hypercholesterolemia Patients.
    Shen T; James DE; Krueger KA
    Pharm Res; 2017 Jan; 34(1):185-192. PubMed ID: 27822850
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Givosiran in acute intermittent porphyria: A personalized medicine approach.
    Poli A; Schmitt C; Moulouel B; Mirmiran A; Talbi N; Rivière S; Cerutti D; Bouchoule I; Faivre A; Grobost V; Douillard C; Duchêne F; Fiorentino V; Dupré T; Manceau H; Peoc'h K; Puy H; Lefebvre T; Gouya L
    Mol Genet Metab; 2022 Mar; 135(3):206-214. PubMed ID: 35058124
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Nonclinical Disposition and Pharmacokinetic/Pharmacodynamic Properties of
    McDougall R; Ramsden D; Agarwal S; Agarwal S; Aluri K; Arciprete M; Brown C; Castellanos-Rizaldos E; Charisse K; Chong S; Cichocki J; Fitzgerald K; Goel V; Gu Y; Guenther D; Habtemariam B; Jadhav V; Janas M; Jayaraman M; Kurz J; Li J; Liu J; Liu X; Liou S; Maclauchlin C; Maier M; Manoharan M; Nair JK; Robbie G; Schmidt K; Smith P; Theile C; Vaishnaw A; Waldron S; Xu Y; Zhang X; Zlatev I; Wu JT
    Drug Metab Dispos; 2022 Jun; 50(6):781-797. PubMed ID: 34154993
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.